Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10745475
APP PUB NO 20160355584A1
SERIAL NO

14913578

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAKEDA PHARMACEUTICAL COMPANY LIMITED1-1 DOSHOMACHI 4-CHOME CHUO-KU OSAKA-SHI OSAKA 541-0045

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Carlsson, Malin Lund, DK 2 2
Staum, Kaltoft Margit Birkerod, DK 2 2
Wagner, Thomas Constance, DE 468 5975

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 18, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 18, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00